用重组α2a干扰素和长春碱治疗转移性肾细胞癌。

Metastatic renal cell cancer treated with recombinant alpha 2a interferon and vinblastine.

作者信息

Massidda B, Migliari R, Padovani A, Scarpa R M, Pellegrini P, Cortesi E, Usai E, Pellegrini A

机构信息

Chair of Clinical Oncology, University of Cagliari, Italy.

出版信息

J Chemother. 1991 Dec;3(6):387-9. doi: 10.1080/1120009x.1991.11739126.

DOI:10.1080/1120009x.1991.11739126

PMID:1819623

Abstract

42 patients with advanced renal cell carcinoma were treated with a combination therapy with interferon alpha 2a (mean dosage 16 x 10(6) U i.m. 3 times/week) and vinblastine (0.1 mg/Kg every 21 days). 12 patients (28.5%) had a positive response. Of them 1 presented a complete response (2.38%), 5 a partial response (11.9%) and 6 a stable disease (14.2%). No significant side effects were observed apart from the flu-like syndrome (all patients) and a moderate leukopenia (45.2%). The median duration of responses was 10+ months (range 3-37 months). At 4-year follow-up the median survival time was 16.0 months (range 4-37 months).

摘要

42例晚期肾细胞癌患者接受了α-2a干扰素（平均剂量16×10⁶单位，肌肉注射，每周3次）与长春碱（每21天0.1mg/kg）联合治疗。12例患者（28.5%）有阳性反应。其中1例完全缓解（2.38%），5例部分缓解（11.9%），6例病情稳定（14.2%）。除流感样综合征（所有患者）和中度白细胞减少（45.2%）外，未观察到明显副作用。反应的中位持续时间为10多个月（范围3 - 37个月）。在4年随访时，中位生存时间为16.0个月（范围4 - 37个月）。